Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics, Inc. furnished an updated corporate overview presentation as part of a current report under Regulation FD. The presentation is attached as Exhibit 99.1 and is also available on the company’s website, providing an overview of its business for investors and other stakeholders. The company states that this material is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings unless specifically referenced.
Biosion, Inc. and its wholly owned subsidiary Bonita Biotech (HK) Limited report their ownership of Aclaris Therapeutics, Inc. common stock on an amended Schedule 13G. Bonita Biotech (HK) Limited holds 11,281,950 shares of common stock, representing 9.4% of the class, with sole voting and dispositive power.
The filing explains that a warrant originally held by Biosion, Inc. for 11,281,985 shares was assigned to Bonita Biotech (HK) Limited on December 9, 2025 and then exercised on a cashless basis, resulting in issuance of 11,281,950 shares on December 15, 2025. The 9.4% figure is based on 119,624,542 shares of Aclaris common stock, which includes 108,342,592 shares outstanding as referenced in a prior Form 8-K and the new shares issued to Bonita Biotech (HK) Limited. The reporting persons certify the shares are not held to change or influence control of Aclaris.
Aclaris Therapeutics (ACRS) reported Q3 2025 results. Total revenue was $3.299 million (contract research $0.485M; licensing $2.814M). Operating expenses rose on pipeline investment, with R&D at $13.028 million and G&A at $4.871 million. The company recorded non‑cash royalty income of $0.716 million from the OLUMIANT royalty sale structure.
Net loss was $14.614 million versus $7.586 million a year ago, reflecting higher development spend. Year‑to‑date, net loss was $45.128 million. The balance sheet showed cash, cash equivalents and marketable securities of $167.2 million as of September 30, 2025, and stockholders’ equity of $120.1 million. Management states its resources are sufficient for more than 12 months from issuance. Shares outstanding were 108,345,239 as of October 31, 2025.
Segment data highlight therapeutics as the primary driver: Q3 R&D included bosakitug $3.062M, ATI‑2138 $1.469M, and ATI‑052 $1.837M, alongside discovery $2.340M. Deferred income related to the royalty sale was $3.925M current and $17.492M non‑current.
Aclaris Therapeutics, Inc. furnished an 8-K to share its latest financial update. The company issued a press release announcing financial results for the quarter and nine-month period ended September 30, 2025. This update is provided to keep investors informed about recent operating performance and financial condition.
The press release is attached as Exhibit 99.1 and is furnished rather than filed, which means it is not automatically incorporated into other SEC reports unless specifically referenced. The 8-K is signed on behalf of the company by Chief Financial Officer Kevin Balthaser.
Aclaris Therapeutics will host an in-person and virtual R&D Day on October 14, 2025 at 8:00 a.m. ET, with a live webcast available on the Investors Events page. The accompanying company presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The information in Item 7.01 and Exhibit 99.1 is not deemed “filed” under the Exchange Act or Securities Act, except if expressly incorporated by reference.